Please ensure Javascript is enabled for purposes of website accessibility

Here's Why AnaptysBio, Inc. Slipped on Friday

By Cory Renauer – Nov 9, 2018 at 5:21PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The clinical-stage biotech stock slid despite a third-quarter report that didn't contain any surprises.

What happened

Shares of AnaptysBio, Inc. (ANAB -1.04%), a clinical-stage biotechnology company with a focus on treating inflammation, fell following a third-quarter earnings report released after the bell on Thursday. Despite a lack of significant news, the stock fell 11.1% on Friday.

So what 

AnaptysBio reported $5 million in revenue during the third quarter of 2018, which came entirely from Tesaro (NASDAQ: TSRO), a collaboration partner that advanced TSR-042 into a phase 3 trial earlier this year. Tesaro's contribution didn't do much to offset rising operating expenses, and AnaptysBio reported a $16.8 million loss during the three months ended Sept. 30. 

Angry stock trader looking at computer screens.

Image source: Getty Images.

AnaptysBio is still in early development stages and hasn't started holding earnings calls with analysts yet. If it had, analysts may have questioned the company's willingness to begin a 100-patient study as a treatment for adults with chronic rhinosinusitis exacerbated by nasal polyps (CRSwNP) without human proof of concept data from a smaller trial.

Now what

AnaptysBio thinks (CRSwNP) affects around 1.3 million adults in the U.S. and around a third need more than standard care. If the Eclipse study with the drug etokimab succeeds, this company's $1.7 billion market cap could soar. Etokimab's early results with severe asthma patients were encouraging, and there's an association with CRSwNP, but we won't be able to pin any significant value to the drug candidate for this indication until the company presents top-line results in the second half of 2019.

The last half of 2019 will be an exciting one for AnaptysBio's wholly owned candidates. In addition to etokimab's CRSwNP results, investors can also look forward to data from the 300-patient Atlas study with eczema patients. The company's second wholly owned candidate in clinical stage trials, ANB019, is also expected to produce initial results for two inflammatory conditions in need of new treatment options: generalized pustular psoriasis and palmoplantar pustulosis.

Cory Renauer has no position in any of the stocks mentioned. The Motley Fool recommends AnaptysBio. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

AnaptysBio Stock Quote
AnaptysBio
ANAB
$25.14 (-1.04%) $0.27

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
329%
 
S&P 500 Returns
106%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/26/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.